Saw your post@ Superfluous and agree this is an interesting one. At a high level, there is a large market for CCTA (Coronary Computed Tomography Angiogram) and its interpretation. In the US it’s a $US 4.4b market, and AYA has a relatively small market cap of around $170m.  

AYA have FDA approval for the “Coronary Anatomy Platform” software and have this month received FDA approval for the second Plaque Module. With the Coronary Flow module to be submitted to the FDA later in the year and approval expected in the first quarter of next CY.  

AYA's offering appears to be superior to the US competition, Heartflow and Cleerly.  AYA software providing an actionable report within 10 minutes and appears to integrate better with the patient workflow.

AYA have a foothold in the US (Cone Health, Tanner Health and N/E Georgia Health) and now a small revenue.   Appear to be doing the smart thing in nearly giving away the product in the first instance.

CEO John Konstantopoulos helped develop the software and has around 9% of the company.  Success almost wholly dependent on how they execute in the US.  Would be interested to know if any of the Straw-medicos have a view/experience in relation to AYA?  (Apparently the only current use in Australia has been at the Cardiac Center Wollongong).